Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial

被引：0
|
作者：
D Arnold
W Voigt
P Kiewe
C Behrmann
S Lindemann
S Reif
H Wiesinger
M Giurescu
E Thiel
H-J Schmoll
机构：
[1] Martin Luther University,Department of Hematology and Oncology
[2] Oncology and Transfusion Medicine,Department of Hematology
[3] Charité Campus Benjamin Franklin,Department of Radiology
[4] Martin Luther University,undefined
[5] Bayer Schering Pharma AG,undefined
[6] Global Medical Development Oncology,undefined
[7] Bayer Schering Pharma AG,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
dose-limiting toxicity; epothilone; maximum tolerated dose; phase I; refractory solid tumours; sagopilone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1241 / 1247
页数：6
相关论文
共 50 条
  • [1] Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial
    Arnold, D.
    Voigt, W.
    Kiewe, P.
    Behrmann, C.
    Lindemann, S.
    Reif, S.
    Wiesinger, H.
    Giurescu, M.
    Thiel, E.
    Schmoll, H-J
    BRITISH JOURNAL OF CANCER, 2009, 101 (08) : 1241 - 1247
  • [2] Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors
    Schmid, P.
    Kiewe, P.
    Possinger, K.
    Korfel, A.
    Lindemann, S.
    Giurescu, M.
    Reif, S.
    Wiesinger, H.
    Thiel, E.
    Kuehnhardt, D.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 633 - 639
  • [3] Weekly administration of ZK-EPO, a novel third-generation epothilone, in patients with refractory solid tumors: Results of a phase I trial
    Arnold, Dirk
    Voigt, Wieland
    Kiewe, Philipp
    Behrmann, Curd
    Lindemann, Stefanie
    Reif, Stefanie
    Giurescu, Marius
    Thiel, Eckhard
    Schmoll, Hans-Joachim
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [4] A phase I clinical pharmacokinetic study of sagopilone (ZK-EPO), a novel first fully synthetic epothilone, in Japanese patients with refractory solid tumors
    Minami, Hironobu
    Araki, Kazuhiro
    Kitagawa, Koichi
    Mukai, Hirofumi
    Mukohara, Toru
    Kodama, Keiji
    Ando, Yuichi
    Narabayashi, Masaru
    Sasaki, Yasutsuna
    Mera, Kiyomi
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [5] Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma
    Wenk, D.
    DeConti, R. C.
    Urbas, P.
    Andrews, S.
    Sondak, V. K.
    Maker, N.
    Weber, J. S.
    Daud, A. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma
    Daud, A.
    Weber, J.
    Urbas, P.
    Andrews, S.
    Maker, N.
    Sondak, V. K.
    DeConti, R. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate
    Klar, Ulricj
    Hoffmann, Jens
    Giurescu, Marius
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (11) : 1735 - 1748
  • [8] Phase II Study of the Novel Epothilone Sagopilone (ZK-EPO) in Patients with Progressive Metastatic Breast Cancer.
    Campone, M.
    Dittrich, C.
    Cufer, T.
    Dudov, A.
    Phan, Dao P.
    Schmelter, T.
    Giurescu, M.
    Martin, M.
    CANCER RESEARCH, 2009, 69 (24) : 858S - 859S
  • [9] A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer
    Rustin, G.
    Reed, N.
    Jayson, G. C.
    Ledermann, J. A.
    Adams, M.
    Perren, T.
    Poole, C.
    Lind, M.
    Persic, M.
    Essapen, S.
    Gore, M.
    Calvert, H.
    Stredder, C.
    Wagner, A.
    Giurescu, M.
    Kaye, S.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2411 - 2416
  • [10] A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors.
    Schmid, P
    Kiewe, P
    Kuehnhardt, D
    Korfel, A
    Lindemann, S
    Giurescu, M
    Reif, S
    Thiel, E
    Possinger, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 147S - 147S
12345